Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cingulate Inc. (CING)

Cingulate extends Chief Medical Officer Matthew Brams' trial period to December 31, 2026

Neutral Impact 2 of 5 leadership Written later

Cingulate Inc. amended the employment agreement of Matthew N. Brams, its Executive Vice President and Chief Medical Officer, on September 30, 2026. The amendment extends the trial period for his full-time employment from September 30, 2026 to December 31, 2026. This is an administrative change to an executive's employment terms and does not disclose any financial results or new compensation figures.

Key points

  • Amendment No. 2 to the employment agreement between Cingulate Therapeutics LLC and Matthew N. Brams was entered into on September 30, 2026, effective January 1, 2026 for the underlying agreement.
  • The trial period for Mr. Brams' full-time employment was extended from September 30, 2026 to December 31, 2026.
  • The full amendment is filed as Exhibit 10.1 to the 8-K.

The filing

CompanyCingulate Inc. (CING)
Form8-K, current report
Filed with the SECOct 2, 2026, 4:30 PM ET
Accession number0001493152-26-045527

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.